Follow The Filings

NBIX Neurocrine Biosciences Inc.

Health Care, filed as NEUROCRINE BIOSCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 3 Owners
  • Max 1.9%
  • $954M
  • 1 reduce 1 small

In 2026 Q2 Nathan Fischel trimmed Neurocrine Biosciences.

Who owns this now

Largest portfolio weights among holders, up to 1.9% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 1.9%
  2. Dodge & Cox Add 0.49%
  3. Palo Alto Investors 0.42%

Who owns NBIX

Sorted by value, long equity only, as of 2026 Q2.

History
Dodge & Cox 0.49%, was 0.39% Small add +2.3% 5,584,707 $941M History
Nathan Fischel, Dafna Capital Management 1.9%, was 2.1% Reduce −18.2% 57,769 $9.7M History
Palo Alto Investors 0.42% Hold 18,117 $3.1M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NBIX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NBIX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $77.8M sold by 15 insiders under 10b5-1 plans
  1. David W. Boyer Chief Corp. Affairs Officer
    Planned sale
    $130K 826 shares at $157.45 8.7% of stake
    Traded Sep 14 Filed Sep 15
    ↗
  2. Matt Abernethy CFO
    Planned sale
    $363K 2,311 shares at $157.20 5.1% of stake
    Traded Sep 14 Filed Sep 15
    ↗
  3. Eric Benevich Chief Commercial Officer
    Planned sale
    $333K 2,154 shares at $154.61 3.2% of stake
    Traded Sep 9 Filed Sep 10
    ↗
  4. Leslie V Norwalk Director
    Planned sale
    $228K 1,250 shares at $182.01 44% of stake
    Traded Jul 28 Filed Jul 30
    ↗
  5. Ingrid Delaet Chief Regulatory Officer
    Planned sale
    $791K 4,367 shares at $181.02 21% of stake
    Traded Jul 10 Filed Jul 13
    ↗
  6. Darin Lippoldt Chief Legal Officer
    Planned sale
    $1.8M 10,000 shares at $179.60 15% of stake
    Traded Jul 9 Filed Jul 13
    ↗
  7. Ingrid Delaet Chief Regulatory Officer
    Planned sale
    $2.6M 14,571 shares at $178.65 47% of stake
    Traded Jul 7–9 Filed Jul 9
    ↗
  8. Darin Lippoldt Chief Legal Officer
    Planned sale
    $1.7M 10,000 shares at $170.15 15% of stake
    Traded Jun 26–29 Filed Jun 30
    ↗
  9. Stephen A Sherwin Director
    Planned sale
    $4.1M 25,000 shares at $165.32 61% of stake
    Traded Jun 5 Filed Jun 9
    ↗
  10. Leslie V Norwalk Director
    Planned sale
    $210K 1,250 shares at $168.06 31% of stake
    Traded Jun 4 Filed Jun 8
    ↗
  11. Julie Cooke Chief Human Resources Officer
    Planned sale
    $5.8M 36,937 shares at $156.22 62% of stake
    Traded Jun 2 Filed Jun 4
    ↗
  12. Ingrid Delaet Chief Regulatory Officer
    Planned sale
    $354K 2,261 shares at $156.71 12% of stake
    Traded May 29 Filed Jun 2
    ↗
  13. Jude Onyia Chief Scientific Officer
    Planned sale
    $1.8M 11,000 shares at $160.25 30% of stake
    Traded Jun 1 Filed Jun 2
    ↗
  14. Jude Onyia Chief Scientific Officer
    Planned sale
    $1.7M 11,000 shares at $155.53 30% of stake
    Traded May 27 Filed May 29
    ↗
  15. David W. Boyer Chief Corp. Affairs Officer
    Planned sale
    $609K 3,888 shares at $156.64 33% of stake
    Traded May 26 Filed May 28
    ↗

Also filed in the last 12 months, not counted as buying or selling: 75 option exercises, 57 share withholdings for taxes, 20 stock grants, 6 gifts, and 1 sale to cover taxes.

Congress

1 member of Congress traded NBIX in the last three years: 1 buy and 1 sale.

All Congress trades
  1. Lisa C. McClain R-MI-9Spouse Partial sale $1K–$15K Jun 17, 2025 filed Aug 13, 2025
  2. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jun 11, 2025 filed Aug 13, 2025

SEC filings

Recent issuer filings from EDGAR, 7 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
10-Q Filing Doc
8-K/A 9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated about 2 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.89B $2.36B $2.86B
Gross profit * $1.85B $2.32B $2.81B
Gross margin * 97.9% 98.6% 98.2%
Net income $249.7M $341.3M $478.6M
Net margin * 13.2% 14.5% 16.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.61B $1.72B $2.52B
Total non-current assets * $1.64B $1.99B $2.11B
Total assets $3.25B $3.72B $4.63B
Total current liabilities $654.8M $507.7M $743.4M
Total non-current liabilities * $364.6M $621.3M $635M
Total equity $2.23B $2.59B $3.25B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $389.9M $595.4M $782.7M
Cash from investing -$467.1M -$126.8M -$264.4M
Cash from financing $65.3M -$486.7M -$38.3M
Net change in cash -$11.6M -$18.1M $480M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.